Drugs / PERZINFOTEL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00073034 | Jan → Dec 2004 | diabetes mellitus, diabetic polyneuropathy | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERZINFOTEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL452461 ↗ |
| Known as | EAA-090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073034 ↗ |
| Modality | Small molecule | — CHEMBL452461 ↗ |
| Route | Oral | “3 fixed oral doses of EAA-090” NCT00073034 ↗ |